207 related articles for article (PubMed ID: 34896571)
1. Osteosarcoma from the unknown to the use of exosomes as a versatile and dynamic therapeutic approach.
Santos A; Domingues C; Jarak I; Veiga F; Figueiras A
Eur J Pharm Biopharm; 2022 Jan; 170():91-111. PubMed ID: 34896571
[TBL] [Abstract][Full Text] [Related]
2. Mesenchymal Stem Cell Derived Exosomes as Nanodrug Carrier of Doxorubicin for Targeted Osteosarcoma Therapy via SDF1-CXCR4 Axis.
Wei H; Chen F; Chen J; Lin H; Wang S; Wang Y; Wu C; Lin J; Zhong G
Int J Nanomedicine; 2022; 17():3483-3495. PubMed ID: 35959282
[TBL] [Abstract][Full Text] [Related]
3. A Nanodrug Consisting Of Doxorubicin And Exosome Derived From Mesenchymal Stem Cells For Osteosarcoma Treatment In Vitro.
Wei H; Chen J; Wang S; Fu F; Zhu X; Wu C; Liu Z; Zhong G; Lin J
Int J Nanomedicine; 2019; 14():8603-8610. PubMed ID: 31802872
[TBL] [Abstract][Full Text] [Related]
4. Multimodal transfer of MDR by exosomes in human osteosarcoma.
Torreggiani E; Roncuzzi L; Perut F; Zini N; Baldini N
Int J Oncol; 2016 Jul; 49(1):189-96. PubMed ID: 27176642
[TBL] [Abstract][Full Text] [Related]
5. Transfer of exosomal microRNAs confers doxorubicin resistance in osteosarcoma cells.
Cai T; Zhang C; Zhan T
Mol Med Rep; 2023 Apr; 27(4):. PubMed ID: 36866739
[TBL] [Abstract][Full Text] [Related]
6. Application of tumor-targeting peptide-decorated polypeptide nanoparticles with doxorubicin to treat osteosarcoma.
Qiu R; Sun D; Bai Y; Li J; Wang L
Drug Deliv; 2020 Nov; 27(1):1704-1717. PubMed ID: 33305647
[TBL] [Abstract][Full Text] [Related]
7. Active targeting schemes for nano-drug delivery systems in osteosarcoma therapeutics.
Shi P; Cheng Z; Zhao K; Chen Y; Zhang A; Gan W; Zhang Y
J Nanobiotechnology; 2023 Mar; 21(1):103. PubMed ID: 36944946
[TBL] [Abstract][Full Text] [Related]
8. Co-delivery of doxorubicin and paclitaxel by reduction/pH dual responsive nanocarriers for osteosarcoma therapy.
Li Y; Hou H; Zhang P; Zhang Z
Drug Deliv; 2020 Dec; 27(1):1044-1053. PubMed ID: 32633576
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin loaded Polymeric Nanoparticulate Delivery System to overcome drug resistance in osteosarcoma.
Susa M; Iyer AK; Ryu K; Hornicek FJ; Mankin H; Amiji MM; Duan Z
BMC Cancer; 2009 Nov; 9():399. PubMed ID: 19917123
[TBL] [Abstract][Full Text] [Related]
10. Activation of Dynamin-Related Protein 1 and Induction of Mitochondrial Apoptosis by Exosome-Rifampicin Nanoparticles Exerts Anti-Osteosarcoma Effect.
Chen W; Lin W; Yu N; Zhang L; Wu Z; Chen Y; Li Z; Gong F; Li N; Chen X; He X; Wu Y; Zeng X; Yueh Y; Xu R; Ji G
Int J Nanomedicine; 2022; 17():5431-5446. PubMed ID: 36426375
[TBL] [Abstract][Full Text] [Related]
11. Polymeric Nanocarriers for Drug Delivery in Osteosarcoma Treatment.
Gu X; Ding J; Zhang Z; Li Q; Zhuang X; Chen X
Curr Pharm Des; 2015; 21(36):5187-97. PubMed ID: 26412359
[TBL] [Abstract][Full Text] [Related]
12. Application of nanoparticles in drug delivery for the treatment of osteosarcoma: focussing on the liposomes.
Liang W; Dong Y; Shao R; Zhang S; Wu X; Huang X; Sun B; Zeng B; Zhao J
J Drug Target; 2022 Jun; 30(5):463-475. PubMed ID: 34962448
[TBL] [Abstract][Full Text] [Related]
13. A33 antibody-functionalized exosomes for targeted delivery of doxorubicin against colorectal cancer.
Li Y; Gao Y; Gong C; Wang Z; Xia Q; Gu F; Hu C; Zhang L; Guo H; Gao S
Nanomedicine; 2018 Oct; 14(7):1973-1985. PubMed ID: 29935333
[TBL] [Abstract][Full Text] [Related]
14. Bone-targeting exosome nanoparticles activate Keap1 / Nrf2 / GPX4 signaling pathway to induce ferroptosis in osteosarcoma cells.
Chen W; Li Z; Yu N; Zhang L; Li H; Chen Y; Gong F; Lin W; He X; Wang S; Wu Y; Ji G
J Nanobiotechnology; 2023 Sep; 21(1):355. PubMed ID: 37775799
[TBL] [Abstract][Full Text] [Related]
15. A chitosan-dipotassium orthophosphate hydrogel for the delivery of Doxorubicin in the treatment of osteosarcoma.
Ta HT; Dass CR; Larson I; Choong PF; Dunstan DE
Biomaterials; 2009 Jul; 30(21):3605-13. PubMed ID: 19345993
[TBL] [Abstract][Full Text] [Related]
16. Exosomes and osteosarcoma drug resistance.
Fu H; Wu Y; Chen J; Hu X; Wang X; Xu G
Front Oncol; 2023; 13():1133726. PubMed ID: 37007086
[TBL] [Abstract][Full Text] [Related]
17. Folic acid decorated metal-organic frameworks loaded with doxorubicin for tumor-targeted chemotherapy of osteosarcoma.
Xu W; Lou Y; Chen W; Kang Y
Biomed Tech (Berl); 2020 Apr; 65(2):229-236. PubMed ID: 31605575
[TBL] [Abstract][Full Text] [Related]
18. Exosomes: Cell-Derived Nanoplatforms for the Delivery of Cancer Therapeutics.
Kim H; Kim EH; Kwak G; Chi SG; Kim SH; Yang Y
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374978
[TBL] [Abstract][Full Text] [Related]
19. Tumor cell-derived exosomes home to their cells of origin and can be used as Trojan horses to deliver cancer drugs.
Qiao L; Hu S; Huang K; Su T; Li Z; Vandergriff A; Cores J; Dinh PU; Allen T; Shen D; Liang H; Li Y; Cheng K
Theranostics; 2020; 10(8):3474-3487. PubMed ID: 32206102
[TBL] [Abstract][Full Text] [Related]
20. Exosome mimetics derived from bone marrow mesenchymal stem cells deliver doxorubicin to osteosarcoma
Wang J; Li M; Jin L; Guo P; Zhang Z; Zhanghuang C; Tan X; Mi T; Liu J; Wu X; Wei G; He D
Drug Deliv; 2022 Dec; 29(1):3291-3303. PubMed ID: 36352741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
